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Abstract
Background
Steroid resistant acute vascular rejection (A VR) is
great obstacle in successful renal transplantation
(KTx). The aim of this work was to evaluate the
outcome of histologically confirmed acute vascular
rejection-which of occurred in severe aggressive
form in 39 patients following kidney transplantation
as well as to study the outcome of therapy. These
cases were chosen from Inoo renal allograft
recipients who underwent kidney transplantation in
the period between March, 1976 and April 1997 in
Urology-Nephrology Center, Mansoura, Egypt.
Me/hods
Statistical analysis of risk factors leading to A VR
was carried out. The outcome of different rescue
therapies used for A VR as well as graft survival
[unct ions were also analyzed.
Results
Survival analysis for grafts with A VR revealed
60%, 53%, 30 %, 0% graft survival at 1,2,5, I 0 ys
respectively alter Tx.
A statistically significant difference was found in
comparison to patients who only experienced acute
Corre'\!10llt/t'IIC'(' and rifjiJrillf req/l(',\'H to: Dr. Mohamed A. Ghoneim.
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cellular rejection (90 %, 84 %, 71 %, 46 % graft
survival at 1,2,5, I 0 years post- K.Tx respectively) or
patients who passed without rejection in their post-
transplantation follow up (95 %, 91.3 %, 83.3%
65.5% graft survival at 1,2,5, I 0 ys respectively).
No statistically significant difference on the overall
graft survival between the different modalities of
therapy was noted. Steroid pulses --plasma exchange
were given for 14 patients with A VR, whereas ATG,
MAS ± plasma exchange were added to steroid
resistant cases (25 patients).
Logistic regression analysis of these data showed that
prior blood transfusion, donor-recipient
consangumuy, rctransplantation are the most
significant variables related to occurrence of A VR
after kidney transplantation.
At last follow up, 14 patients 05.9 %) were living
with functioning grafts, 16 patients (41 %) were living
on dialysis, 5 patients died with functioning grafts
(12.8%) and 4 patients (10.25%) died with failed
grafts.
In conclusion: A VR remains a major obstacle for
renal transplantation as it markedly impaired graft
survival and responded poorly to therapy. Prior blood
transfusion decreased the incidence of A VR whereas
rctransplantation and unrelated donation account
significantly to the occurrence or A VR after renal Tx.
Key words: Acute vascular rejection; ATG; kidney
transplantation; MAS; plasma exchange
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Introduction
Early steroid resistant predominantly vascular acute
rejection is a barrier to successful kidney
transplantation CKTx) [1,2].
This despite the sophisticated use of immuno-
suppressive drugs and improved understanding of
cellular and humoral host responses in transplanted
organs during recent years. Several reports
considred early vascular rejection, occurring within
3 months after renal Tx, as one of the most
important predicting variable for both early and late
graft loss [3,4]. The incidence of acute vascular
rejection (A VR) after K Tx was reported in one
series to be as high as 26 % [5] and that the risk of
developing vascular rejection decreased in patients
using Ciclosporin (Cs), (as compared with
Azathioprine), those having less HLA-DR
mismatches and short duration of cold ischaemia
[3]. It was also reported that previous
transplantation possibly increase the incidence and
severity of A VR [3J. Living unrelated
transplantation was found to be attended with severe
irreversible A VR, poor graft outcome as well as
several medical and surgical complications [6,7].
Acute cellular rejection (ACR) usually responds
well to steroids but the proper treatment of AVR is
still a problem. In general, the success of treatment
of vascular rejection is still poor [8J.
Several therapeutic trials were conducted to evaluate
the efficacy of antithymocyte polyclonal antibodies
(ATG) in steroid resistant rejection (SRR) in
patients treated with prednisolone and azathioprine
and also in patients with (Cs) [9,10]. Successful use
of ATG was reported in 70 % of SRR on treatment
with triple immunosuppression [I I].
Table 1. Patients demographics
OKT3 (monoclonal antibodies) was found to
successfully reverse acute rejection in most patients
who have failed to respond to prolonged courses of
high doses of steroids [12] and in many instances to
ATG as well. The monoclonal antibodies (MAB) are
specifically directed to the CD3 molecules on
lymphocytes and consequently is expected to be a
rescue therapy for A VR [13,14 J'
Plasma exchange (PE) was recognized as an
important approach to therapy of SRR predominantly
AVR which is refractory to conventional
immunosuppression by removal of Iymphocytotoxic
antibodies [ISJ. PE has been used with success either
alone [16] or in combination with ATG, steroid,
OKT3 to reverse AVR [17, 18J.
The aim of the present study was to evaluate the
impact of AVR on graft survival as well as to evaluate
the efficacy of different therapeutic modalities to treat
biopsy proven AVR following kidney transplantation.
Materials and methods
In tbe period from 1976 to 1997,1000 consecutive
kidney transplantations were carried out in our
Center. All received their grafts from living donors.
Of these, 39 patients had suffered episodes of
histologically-proven acute vascular rejection CAVR).
They were 10 females, and 29 male patients wi th a
mean age of 30.4 ± 10.9 years. Patient characteristics
and the original kidney discase are summarized in
tables 1,2 respectively.
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Table 2. Original kidney disease
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Diagnosis Non-Vasculitic (1/0=961 patients}Yosculitic group (110=39 patients)
110 % no %
7 21.9 76 9.7
I 3.1 125 16.0
4 12.4 36 4.6
2 6.3 41 5.2
0 0 13 J.7
3 9.4 24 3.1
0 0 20 2.6
........ _--.- ..............••.•........ .....................................
<0.04














End stage kidney disease
• Significant at P ..,0.05
luununologic variables
The A VR group included 33 patients who had there
Ist transplant and in six cases it was the second. All
patients received their grafts from living donors. A
negative T lymphocyte cross match was a
prerequisite for transplantation. Seventeen patients
(43.6%) received non-specific blood transfusion prior
to transplantation. Twenty-three were living related
kidney transplantation whereas 16 patients received
their grafts from unrelated or emotionally- related
donors (table 3).
Table 3 Immunological variables


























vusculitic group (1/=39 patients)
no Ik no '*
23 (58.97) 780 (81.2)
16 (41.02) 181 (10.8)
30 (76.9) 826 (86.0)
9 (23.1 ) 135 (14.0)
3 (7.7) 66 (7.0)
8 (20.5) 147 (15.6)
22 (56.4) 553 (57.5)
6 ( 15.4) 156 ( 16.5)
0 (0) 39 (4.1)
0 13 (1.4 )
36 (92.3) 920 (95.7)
3 (7.7) 28 (2.9)
22 (56.4) 312 (24.7)
9 (52.9) 281 (43.3)
3 ( 17.6) 121 (18.6)
5 (29.4) 247 <38.1 )
3:l (84.6) 928 (96.6)
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Over the years, different protocols of immurno-
suppression were employed. These were previously
published r 19,20] and are displayed in table 4.
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Table 4. Post-transplant factors
s/nsculitic group (110=39patients)
no %















Acute rejection was determined according to
commonly accepted clinical, laboratory criteria.
Fine needle aspiration cytology and ultrasound
guided percutaneous (Pe) needle biopsy were
carried out for patients showing deterioration of
graft function and whenever acute rejection was
suspected. Graft biopsies were revised according to
Banff's classification [21] and severe cases of A VR
(Banff grade III) were only included in this study.
The diagnosis of A VR was made by the following
findings: Intimal arteritis (endovasculitis),
proliferation and swelling of endothelium with
edema of the intima and/or mononuclear cell
infiltration and adherence of mononuclear cells to
endothelium. Fibrinoid necrosis of small arteries
and arterioles, thrombosis of hilar and arcuate
arteries. Platelet aggregates and fibrin thrombi in
glomerular and peritubular capillaries and interstitial
hemorrhage [21].
Management of A VR
Once diagnosis of A VR was established. cases were
initially treated by methyl predinsolone (500 mg,
intravenous for 5 consecutive days). In 9 cases this
was the only modality used. In 5 cases, additional
plasma-exchange was neede.
Cases with unfavourable response to steroids
received additional therapies as ATG or MAB.
These were given for 25 patients. Nineteen patient
out of them required additional plasma exchange as
well.
ATG (Fresinius, FDG) was given at a dose of 3-5
mg/kg/day as 4 hours slow infusion for 10-14 days.
Alternatively OKT3 (monoclonal AB) was given as
an intravenous bolus of Smg daily for 10 days.
Plasma exchange was carried out on alternate days
for 5 sessions. Cyclosporin was withheld, to be
reintroduced on the 8th day of therapy.
A successful response to ATG, OKT3 ± plasma
exchange was defined as improvement in serum
creatinine level or return to prerejection values with
(25.6) 289 (30.1)
( 12.8) 167 ( 17.4)
(61.5) 505 (52.5)
(53.8) 732 (71.6)
(461 ) 229 23.8
0.42
0.002
improvement of clinical and biological parameters of
acute rejection.
Statistical analysis
Statistical analysis was carried out using SPSS
package. For uni-variate analysis, student T test, Chi-
square test were used. Multivariate analysis was
carried out using COX logistic regression. Graft
survival was computed using Kaplan-Meier method
[22J. Differences were compared using log rank test.
Results
Patients demographics data arc shown in table I.
There was no significant difference, regarding age.
sex of the donors or recipients, between patients who
developed acute vascular rejection (A VR) and those
who did not.
The original kidney diseases arc summarized in table
2. There was a statistically significant difference
between the above groups on univariate analysis (p <
0.04).
The immunological variables arc summarized in table
3. Out of these variables, three factors showed
statistically significant difference namely: donor/
reerpient consangunuty, pretransplant blood
transfusion, number of grafts received.
AVR was significantly higher in patients who
received their grafts from unrelated donors and in
retransplanted patients whereas lower incidence was
found in patients who received blood transfusion prior
lO transplantation, however the number of transfusion
received did not have an impact.
The initial imrnunosuprcssion regimens as well as the
number of acute rejection episodes encountered arc
outlined in table 4. The initial irnmunosuprcssion did
not have an impact on the incidence of A VR,
morcover it could be observed that the frequency of
acute rejection and eventual development of chronic
rejection was higher significantly in patients who
developed A VR (table 4,5).
The multivariate analysis (table 6) indicated that
only three factors act independently namely prior
hlood transfusion, donor-recipient consanguinity
and retransplantation. So, unrelated transplantation,
retransplantation were found to predispose to A VR
(P<O.OI,<O.OOI respectively.)
Graft survival among patients who did not
















rejection and patients with acute vascular rejection i,
illustrated in figure I. Differences are statitically
significant (P < 0.00 I). Patients who did not have
rejection have 5 years graft survival of 83.27% ± 2.4..J.
and patients who develop acute cellular rejection had
survival of 71.78% ± 2.04 whereas patients with A VR
have survival of 30.88 % ± 9.23 at 5 years.
P s 0.001 -
Acute Vascular Rejection (n = 39)
5 1510
Time (years)
Fig. I. Kaplan-Meier curves for gran survival of patients who developed acute vascular rejection compared to patients who had acute
cellular rejection and to patients who did not experience acute rejection crives.
Gran survival at 2,5 years post - transplantation
were correlated with treatment modalities adopted.
No clear advantage of any specific regimen is
evident (P > 0.(5) (table 7).
At last follow up, 14 patients (35.9 (!c) were living
with functioning grafts with a mean serum
creatinine of 1.75 ± 1.58 mgldl, 16 pat ierus (41 %)
Tuble 5, Condition at la~t follow up
were on dialysis due to graft failure secondary to
chronic rejection or failure of antirejeciion therapy.
Five patients (12.8 %) died with functioning grafts
due to cardiovascular (4 patients), pulmonary compli-
cations (one patient). Four patients died with failed
grafts (table 5).
Non vascutitic groun (no=96Ipalielll.l)Yuvculiti: Rml/tl (110=39 puticnts)
Living with functioning grans.
Living on dialysis
Died with functioning grafts.













" Graft failure was due to chronic rejection (II paricntv) or lad of response to therapy.
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Table 6. Logistic regression analysis of data in vasculitic group
Releva/lt variables Standard error (SE) ProbablitiesRegression estimate (B)





















Table 7. Impact of adjuvant drug therapies on graft survival
Drugs survival proportion at 2 years survival at 5 years
1- steroid pulses
2- steroid pu lses +PE
3- steroid pulses + ATG or MAB
4- steroid pulses + ATG or MAB +PE
7/ 9 3/ 9
3/ 5 3/ 5





* Significant al Ps 0.05
Discussion
Acute vascular rejection (A VR) as an early
complication of renal transplantation is not usually
amenable to conventional anti rejection therapy. The
question has been raised as to whether in grafts with
severe rejection, treatment should even be
attempted. Few randomized studies were conducted
on this subject [1,23].
In the present study, 39 patients with severe A VR
were studied. The criteria of diagnosis and
stratification of A VR were as described by Solez et
al., 1993 [21 J. It was shown that dividing rejection
into either vascular or interstitial had an important
prognostic significance on both graft survival and
response to therapy [3].
In our work, the overall survival analysis of patients
with A VR showed statistically significant reduction
of graft survival compared to patients with acute
cellular rejection (ACR) and to patients who didn't
develop post-transplantation acute rejection
(P<O.OOI). This confirms previously published
reports by other investigators, who had also found
that early vascular rejection after KT x is strongly
related to development of chronic rejection and graft
loss at 2,5 years after KTx [3,24,25].
Although some possible risk factors for vascular
rejection were identified, the pathogenesis of A VR
is not well understood. Humoral immunity may be
of major importance in the pathogenesis of vascular
rejection after KTx. Three endothelial - associated
antigen systems are known against which antibodies
can be directed. The oldest known system that is
associated with rejection is the HLA system. A
second system was identified in patients with A VR
by detection of antibodies against endothelial cells
and monocytes. Recently, a third system with
allospecific antibodies against human umbilical vein
endothelial cells was demonstrated and was
associated with both occurrence of A VR and poor
graft survival. These data suggest that in A VR,
alloantibodies may be present and directed against a
non - HLA polymorphic alloantigen system present
on endothelial cells and platelets 13].
The hypothesis that humoral immunity plays a major
role in vascular rejection is supported by occasional
successful treatment of vascular rejection with
polyclonal, monoclonal antibodies 126,281 or removal
of antibodies by plasma exchange 131. It was
previously reported that monitoring of antibody
derived cell mediated cytotoxicity (ADCC) could
predict rejection as early as 15 days in advance of any
clinical or biochemical signs of rejection 129,301·
However our own previously published observations
did not confirm these conclusions 1311·
In this study, we attempted to identify the possible
risk factors which are associated with increased
incidence of AVR. The initial univariate analysis had
identified the following factors as significant: original
kidney disease, donor - recipient consanguinity,
pretransplant blood transfusion and the number of
grafts received. Nevertheless, multivariate analysis
using COX - regression model had identified the
following factors as significant and acting
independently namely: Pretransplant blood
transfusion, donor - recipient consanguinity and the
number of grafts received. So this work suggest that
transplantation from unrelated donors,
retransplantation significantly increased the incidence
of A VR after KTx. On the contrary, prior nonspecific
blood transfusion regardless of its frequency,
improved graft survival significantly and patients
were less prone to A VR after K.T x- These results
were approved by other investigators [3.6,7,321.
although some denied the role of prior blood
transfusion l331. It was also noted that patients who
had A VR were more prone for repeated acute
rejection episodes and eventually the development
of higher incidence of chronic rejection.
All patients enrolled in this study had received
steroid pulses initially for the treatment of their
A VR. Subsequently in view of lack of response to
this therapy di fferent additional modalities were
employed: ATG, MAS ± plasma exchange (PE).
Wc could not clearly identify the superiority of any
specific regimen and a decrease in graft survival at
2.5 years was found. It must be noted that in recent
data l5,34,35], utilization of Tacrolirnus was
reported as a potent agent which can reverse A VR
in 65o/c of cases.
In this work, the 5 years graft survival in patients
with A VR was 30.8 %. This reflects a poor
prognosis of A VR. Our results did not support other
reports illustrating the beneficial effect of ATG/ or
MAS on the outcome of A VR 126,27]'
So, on the basis of the study of the potential risk
factors, it is clearly evident that such patients who
are more prone for A VR should receive initially
more potent immunosuppression. Furthurrnorc ATG
or MAS should be administered prophylactically
rather than salvage therapy.
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Alleles H LA-ORB I chez les enfants avec I.:lomémlonéphritc post-srreptococcale aiJ.,'lJë
Resumé: Pour étudicr I'association des alleles HLA-DRB I ct de la glomérulouéphritc aiguë post strcptococcalc
(GNAPS). .12 cnfants avec GNAPS ct 3XO sujcts sains de la même région ont été teste pour les alleles ORB I en
utilisant la methode de polvmcrisation de chaine hvbridation reverse.
Les patients ayant unc GNAPS avaicnt unc fréqucncc accrue des deux ORB I *030 II (-l('.1J YS. 11J.2'X, chez les
controles p= O.()0025) ct DRBI*II05 (:It.1 vs. 15JJ'X, chcz Ics controles. p= O.O()I}7). Ccpcndant aprcs
correction des valcurs de p scule Ia différcncc pour ORB I*(l.\O II reste significative (pe = (l.025). Leurs risqucs
rclatifs sont significarivcmcnt cleves 13.7t. intervale de confinnee (IC) = t.X-7.X ct .1.57. (IC) = I.-l-X.')
rcspcctivcmcnt]. Il 11\ avait pas de difference entre Ics fréqucnccs des deux alleles chcz les patients ct Ics
dogres d'hvpcncnsion. protemuric ct hematurie.
Conclusion: Les alleles ORB I*010 II ct évcntucllcmcnt 1105 coufércnt unc susccptibilité lila GNAPS mais la
gravité de la maladie n'cst pas dctcrminée par ces deux alleles.
Le virus de I'hépatite C comme facteur étiolol.:ique éventuel du syndrome néphrotique idiopathiquc chez
les patients ég~lltiens
Resumé: L'infcction par le virus dc l'hépatitc C (HCY) est associéc ;1 une variété de manifcstations
cxtrahépatiqucs. parmi lesquelies la crvoglobulinénuc et la glomcruloncphritc. La glomérulonéphritc du virus
de I'hépatitc C (HCY) pouruit eonstimer une maladie glomérulairc primaire.
Notre étude porte sur 50 patients adultes égvpticns diagnostiqués comme avant un syndrómc néphrotiquc
idiopathiquc (SN). Nous nvons décrit Ics caracténstiqucs cliniqucs. pathologiqucs ct inununologiqucs dc ces
patients. Unc prevalence nnportante d'infcction ,I HCY a été rotrouvee chez ces patients (.'iO'!!,,), Les facteurs de
risque étudiés ont été la transfusion sanguine (16%). unc intervention chirurgieale (2-l%) cl un traitement
antibilharzicn (7(,%). Unc hépatomégalic a été obscrvée dans 2-lcX, des cas.
Lc t~pc pathologiquc Ic plus Iréqucnuucnt associéc ill'HCY a éré la glomérulonéphritc mcmbranoproliférauvc
(MPGN) (-lX%) Les autrcs tvpcs étaicnt la glomérulosclérosc focale ct scgmcntale (FSGS) dans 12% des cas. la
glomcrulop.uhic extramembraneuse dans X'x, cl la néphrosc lipoïdiquc dans 12%, Les erveglobulines ont crc
détcctécs chez 5J,% dcs IX patients avec HCY ct SN idiopathiquc.
Les patients avant uuc infection li HCY ct unc glomérulonéphritc mcmbranoprolifcrativc avaicnt UIlC
11\pocomplémcntémic ct des anticorps anti-nucléaircs dans -ll.ó% des cas,
En \'IIC de I'évcntucllc association de I'infcction (I HCY ct dc différcntcs glomérulopathics. Uil depistage de
routine du HCY doit étrc pris en consideration chez ces patients. Ccpcndant unc étudc séroépidémiologiquc
erenduo a un nombrc plus important dc patients cst necessaire pour determiner 11IICcveruuelle relation avec unc
infection par HCY.
Etude des formes cliniques de L'hypertension artcrielle dans un service d'uruences medicales it Abidjan
Resumé: Les auteurs crudient Ics formes cliniquc dc l'hypcrtcnsion artcrielle et le rólc aggravaut des chiffrcs
tcnsionncls supéricurs u 2-l0 nun de Hg pour la systoliquc ct 1-l0 nunl-lg pour la diasrotique appelces
Supcrhvpcncnsious artéricllcs chez :l()O adultcs Noirs Africans admis dans Ic service des urgcnccs medicales ,i
Abidjan.
L'hypcrtcnsiou artcrielle qui rcpréscntc X.27% des admissions constituc la principale cause dc mortalité dans cc
service ( 12.')'1., Vcrsus 7.2% pour les aut res affections).
Les complications suivantes ont été notécs: insuffisancc cardiaquc (2Y%). accident vasculaire cérébral (21 %).
cncéphaloparluc (I')'X,). insuffisancc renale (16%). L'association diabete. hypertension artcrielle est noiéc dans
X.lJ% des cas. UIIC mortalité élcvéc est obscrvéc Cll cas d'accidcnt vasculaire cerebral (2.'i.-l%) ct d'insuffisancc
rénale (25%). Lc taux dc mortaité est fortement lié ;'1 I'importancc des chiffrcs tcnsiouncls.
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Réutilisatinn du dialyseur, effet sur l'éfficacité ct la hiocompatibilité
Resumé: Quizc patients SUf hémodialysc de maintien ont été étudiés avant et aprcs réutilisation des dialyscurs i'l
fibres creuses en cuprophane pour évalucr la biocompatibilité et l'cfficacité dil dialyscur.
II y a ell line augmentation statistiquement probante de l'hématocritc et du raux d'hémoglobine ilia fin de la
dialyse. Unc diminution significative des leneocvtes totaux (ucutrophilcs. cosinophilcs) et des plaqueues avec
1111 pic ;'1 15 minutes aprcs le début de la dialyse. puis une augmentation progressive jusqu'a la fin de la dialyse
oil ils ont atteint les valcuts de pré dialyse.
Ces changements ont cu lieu ;'1 la premiere utilisation ct au cours des sessions de réutilisation. La diminution
des ncutrophilcs était moindre avec les dialyscurs réutilisés qu'avec les dialysears utilisés pour la premiere fois.
Le complement terminal du complexe (CTC) était augmenté de maniere probante et a atleint un maximum
aprcs 15 minutes. puis il a duuinué jusqu'á la fin de la dialyse. Ces changements étaient statistiqucmcnt
ruoindrcs .1 la réutilisation qu'au premier usage. [I n'y avait pas de relation entre l'altération du CTC et la
diminution des différents éléments cellulaires. II y nvait unc augmentation du bicarbonate plasm.uiquc ct du pH
.\ la fin de la dialyse. Unc hypoxic ct hypocapuie ont eu lieu peil apres le début de la session de dialyse avec
dialys.u ;'1 acetate. mais clles sont rCYCIlUCS ,lUX valcurs pré dialyse il la fin des deux sessions. Celá peut être
attribué ;\Ia perte de dioxide de carbone dans Ie dialysat avec hvpovcntilation subséqucntc.
La etearcnee de l'uréc. de la creatinine et du phosphore ont montré line logere difference entre la premiere
utilisation et la réutilisarion j'l () et ~ h. avec diminution significative a la fin de la dialyse dans les deux cas.
Ceci pcut être du au fait que l'airc de surface du dialyscur réutilisé a été maintcnuc dans des Iimitcs acccptablcs
(XO-100'X,) par rapport au dialvscur de premier usage.
Le dialvscur réutilisc était en quclquc sorte plus hémocompatiblc que cclui de premier usage. l'activaiion du
complement nc semble pas être Ic seul facteur responsabte des reactions de biocompatibilité durant la dialyse
La dialyse avec rcuulis.uiou peut êtrc line methode Slife. quand une sterilisation appropriéc. un &,lockage
adéquat et un nombrc limité de réutilisations ont été adoptés.
La Iipoprotéine (a) chez Ics tranplantés: Un cas d'étude diniquc prospective conrrêllée
Resumé: Celie étude a été concue pour évalucr l'impact de la transplantation renale (TX) SUf Ie profile des
lipides des patients en insuffisancc renale chroniquc (lRC), Elle comprend trente sujcts normaux (N) de
controle et cent cas d'[RC traites par TX el répartis sur trois groupes.
Groupe I: Dix patients en [RC vus au cours du bilan préopératoirc et suivis cl un ct six mois post TX.
Groupe II: Trente paucnis TX sulvis en période post-operateire SUf un an.
Groupe III: Soixautc transplantés. cxanunés justc aprés une TX rcussic.
Les parametres suiv.uus ont été mcsurcs cl suivis scion Ic plan de ebaque groupe: Taux sériquc de Lp(a).
cholesterol total (CT). triglvcéridcs (TG). HOL. LOL. protéines totales (PT). albumine (Alb) ct creatinine. Unc
etude Duple" des arreres carotides a été faire et suivic sur un an chez dix patients du groupe II choisis
aléatoircmcut.
Les t;IlIX sériqucs de Lpia) ont diuunué significatiyelllent au cours des douzc mois de suivi. Ces taux étaient
significauvcmcnt plus cleves il tout moment en comparaison avec N (p<'{).OOO I en tout).
Outre l'efleer favorable de Tx sur Lp(a) elle a ell des cffcts variables sur les autres parametres des lipides
é\ alués pre et post operution. Alors qu'unc diminution des TG a été obscrvéc (p<O.Ol) I). il ya cu augmentation
du CT (p- ooo I). HOL (p<O.005) et LOL (p<'O.OO I). ll n'y a pas cu de correlation significative entre Lpta)
d'unc part ct d'auirc part l'age. le sexe. la crcauucmic. PT. Alb ou les autre parametres des lipides analyses dans
les divcrscs groupes. Aucun des dix patients examines par Duplex n'a ell un changcruent dans I'athérosclérose
des carotidcs sur unc annéc de suivi,
Conclusion: TX a Uil cffct fa\'orable sur la concentration senque d'un facteur de risque aihcrogcnc réccnuucnt
dccrit. Lpïu). L'abscncc de changemem de I'athérosclérose carotidicnnc dans eeue étude n'cxclus pas le role
largement admis de l'activité atberogene de Lp(a). L'abscncc d'effet dc Lp(a) est probablcmcnt due a
l'augmcntuuon significative du cholestérol HDL aprcs TX.
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Taux lie zinc plasmatiques et intracellulaires (plaquettes) chez les patients en insuffisance rénale
chronique (IRC) traités lie différcnres facons
Resumé: Lcs méchanismcs ct dcgrés de déficicnce en zinc (Zn) au cours de l'urcmic restent lin sujet dc
coutrovcrsc. Lcs résuliats des différcnts modes de traitemerns nc sout pas établis. Le Zn plasmanque nc
represenic qu'unc petite panic du ZII corporel total (environ OSx,). L'évaluation du Zn intracellulairc dans les
celluies dil salig pouruit être plus fiablc Cctte étude a été concue pour évalucr I'état reel du ZII au cours de
l'urémic cl determiner si Ics modulites de traitement de I'IRC (conscrvatricc cl dialytiqucs) pouruient influencer
I'état du Zn. l.'étudc dcvait egalemcut crudier l'cffct d'unc session de dialyse. du type dc dialyse ct du tampon du
dialvsat sur I'état du Zn.
Ccttc étude comprcnd dix sujcts de controle sains ct quarante patients Cll IRC répartis en trois sous-groupes
selon les modalitcs de traitement différcntcs IlO traitement conscrvatcur. IS Cll dialvsc péritonéalc internutente
(DPI) ct 15 Cll hcmodialvsc (HO)I.
Zn a étc niesure par absorption atomique spcctophotométriquc du plasma ct des plaquettes.
Unc diminution statistiquemcnt significative du Zn plasmatiquc ct du Zn des plaqueues a été rctrouvé chez les
patients CII IRC traites par différcnts mevens compares ,111.\ controles (p<':'O.OI). mais il n'v avai: pas de
difference notoire entre Ics sous-groupes d'urémiqucs. II n'y uvait pas de différcncc entre Ics sous-groupes
urémiqucs ct les controles quant aux taux des protéincs plasmatiqucs et de I'albumiuc De plus le Zn
plasmatiquc était notoirement augmcnté (cepcndant toujours plus bas que les controles) ct le Zn des plaqueues
était notoiremcnt diminué (p<O.O I) aprcs unc session de dialyse dans Ics deux sous-groupes DPI ct HD. mais
les differences de ces deux parametres (avant et aprés dialyse) étaicnt insignilïantcs chez les patients DPI
compares ;1 HD.
Unc relation negative significative a été trouvee entre Zn des plaquettes et la clearance dc la creatinine dans Ics
trois sous-groupes urcmiqucs (r=-O.X I p<O.O I chez les patient sous traitement conservarcur. r=-0.72 p<O.O I
dans DPI ct r=-0.76 p<O.O I dans HD) mais il n'y avait pas dc relation entre la duréc de la dialyse et le Zn
plasmanque ou cclui des plaqueues. ni entre le Zn plasmutique et Ic Zn des plaquenes. la créatinémic ct la
clearance. Le Zn plasmutique montrait unc elevation transitoirc notable chcs Ics paticnts HD utilisant lin
tampon dc bicarbonate (11,(,+ 1.1 umol/L) compare il cCU.\ utihsant un tampon acétatc (lJ.1 + l.'l umol/L).
(p<O.O I).
L'on peut conclurc que la mesure du Zn intraccllulairc (plaquettes) a IIItC valeur de diagnostic ct de monitoring
dc l'etut du Zn chez Ics urcmiqucs. Les différentcs modalités de traitement n'influcnt pas sur l'hcmostasc du Zn.
aucun type dc dialyse n'etant superieur sur cc point. L'cffet d'élévation du Zn plasmnatiquc aprcs unc seance
unique dc dialyse ct I'utilisation d'un tampon bicarbonate vcrsus acétate n'erau que transitoire ct dil a
I'hémoconccntration ct ii unc mcillcurc correction de l'acidosc au cours dc la dialvsc.
Contrêlc lie I'hypcrphosphatémie lies patients sous hémodialyse ré~ulicre (HDx) I.ar acetate lie calcium
(AC) versus carbonate lie calcium (CC). Une étude prospective en double aveuglo cruisée
Résumé: Ccttc étude comprcnd quarante patients cn insuffisancc renale chroniquc agés de .17 ,i X3 ans
(moyenne SI.3+ 7) sur HD.\ trois fois par semainc depuis entre -t et l-t-t mois (KIN> 1.2). Un dialvsat ,i acetate
avec unc concentration de calcium de .I mEqfL était utilise, TOilS Ics fixatours de phosphate ont été iutcrroinpus
pour Uil mois.
Les patients ont été répartis sur deux groupes. Groupe I (20 cas) ont rccu du AC alors que Groupe Il (20 cas)
ont rccu du CC cn doses equimolaircs (10 m.mol dc eliaque I.i.d.) pour un mois. Un traitement croisc a été fait
pour un autre mois en mainicnant Ics patients sur Ic mémc regime alimcniairc.
Les taux dc calcium sérique (Ca). calcium ionise (iCa). Phosphore (P). phosphatase alkaline (PA). uréc (U).
creatinine (Cr). ALT. AST. protcincs totales (PT) ct albumine (Alb) ont été mcsurés au dédut ct ti la fin de
eliaque mois de traitement all AC ct Cc.
Le Ca sériquc ct iCa étaicnt significativemcnt plus bas dans le groupe I aprcs AC compares aux taux aprcs CC
(p<O.O I). Des résultats similaircs ont été observes dans Ic groupe Il (p<O.OS).
Dans le groupe II sC1I1 le P senque était significarivcmcnt plus bas aprcs AC compares aux taux aprcs CC
(p<O. OS).
Il n'y avai: pas de difference notoire pour PA. U. Cr. ALT. AST. PT. d'cmbléc et ;i la fin dc eliaque mois de
traitement par AC ct CC (p>0.05 pour chaquc).




I) AC n'cst pas mcillcur que CC dans le controle de I'hypcrphosphatémie.
2) AC peut êt re augmeute sans risque d'hypcrcalcémie .
.1) La vitamine D active ct un dialysat richc cn calcium penvent être utilises pour freiner l'activiié
parathvroidicnnc plus surcmcnt avec AC qu'avcc Cc.
-l) La tolerance du CC est supéricurc.
Réjet vasculaire aigu apres transplantation rénale, évolution ct résultats lie différentes thérapies
Resumé:
IdJI' de bas«
Le rcjct vasculaire aigu (RVA) stéroido-résistant cst considéré comme unc bartiere au succes de la
transplantation renale (RTx). Ccue étude vise ;l étudicr l'évoluuon dcs cas de rcjcts vasculaires aigus prouves
histologiqucmcnt qui ont cu lieu de Iacon aggressive ct grave chez. .I\} patients aprcs transplantation rénalc ct
étudicr les résultats de la therapie. Ces cas faisaicnt partic de 1000 cas de reecveuts d'allogrcffcs renales au
Centre d'Urologic-Néphrologic. Mansoura. Egvptc entre mars In() ct avril I \}\)7 .
.\ Iétluul«
Unc étude statistiquc poussec des facteurs de risque conduisant au RVA <J été faire. Les résultats des différentcs
therapies utilisces dans Ic RVA ainsi que les fonctions du grcffon ont été analyses.
Resultats
L'étudc de survic du grcffon avec RVA a été dc 60%. 5.l'X,. 30%. 0% á 1.2.5 ct lO ans rcspectivcmcnt avec unc
difference statistiqucmcnt significative cn comparaison avec les patients n'ayant eu qu'un rcjet cellulaire aigu
«()()%. X-l%. 71% ct -l6% dc survic du grcffon ii 1.2.5 et lOans post RTx respcctivcmcnt) ou ceux n'ayant pas cu
dc rcjct cn périodc post-transplantation (\}5%. \)1..1%. Xl.3% ct 65.5% dc survie du grcffon ,i 1.2.5 ct lO aus
respect ivcmcnt).
II n'.\ a pas dc différcncc statistiquc sur la survic du greffon entre Ics différcntcs modalilés de traitement Un
traitement de steroide par injection + échange plasmanque a été utilise chcz l-l patients avec RVA. ATG. MAB
+ échange plasmutique ont été ajoutés aux cas stéroido-résistants (25 cas).
L'analvsc de regression des données a montré que la transfusion sanguine. unc consanguinité donneur-
rcccvcur Cl uuc rctransplantation etuient les variabics les plus significativcs rcliécs all RVA aprcs
transplantation renale.
Au deruier suivi. l-l patients (35.1)%) sont vivants avec dcs grcffons fonctionncls. I() patients (-lI %) sout
vivants SOliS dialvsc. 5 patients sons décédés avec dcs grcffons fonctionncls (12.X%) ct -l patients (I (1.25%) sont
décédés avec dcs grcffons non fonctionncls. Ccci montrc bien l'effct néfastc du RVA sur Ic devcnir du grcffon.
En conclusion: Le RVA reste un obstacle majeur pour la RTx car il affeete fortement la survic du grcffon ct
repoud mal il la therapie, Une transfusion sanguine pre transplantation duninuc l'incrdcucc dc RVA alors que
la rctransplanratiou ct Ic don d'organes non reliés contribuents dc rnaniere significative au RVA post RTx.
